Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Neurotoxicol Teratol. 2015 Jun 12;52(0 0):162–169. doi: 10.1016/j.ntt.2015.06.003

Figure 4.

Figure 4

In vivo exposure to HBCDD does not alter the concentration of dopamine or its metabolites in the striatum. Animals received either 0 (control) or 25 mg/kg HBCDD for 30 days and were then evaluated for alterations to (A) dopamine, (B) DOPAC, or (C) HVA in the striatum. Columns represent the mean ± SEM of raw values (ng/mg protein) of 4 control and 6 HBCDD treated animals per experimental group.